

# Triparna Sen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9418814/publications.pdf>

Version: 2024-02-01

39  
papers

3,316  
citations

218677

26  
h-index

302126

39  
g-index

43  
all docs

43  
docs citations

43  
times ranked

4467  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy. <i>Cancer Research</i> , 2022, 82, 472-483.	0.9	18
2	Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts. <i>Nature Communications</i> , 2022, 13, 2144.	12.8	18
3	WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. <i>Cell Reports</i> , 2022, 39, 110814.	6.4	43
4	Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1014-1031.	1.1	31
5	Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation. <i>Cancer Discovery</i> , 2021, 11, 3028-3047.	9.4	66
6	An optimized NGS sample preparation protocol for in vitro CRISPR screens. <i>STAR Protocols</i> , 2021, 2, 100390.	1.2	2
7	Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity. <i>Cancer Cell</i> , 2021, 39, 973-988.e9.	16.8	93
8	MYC Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2021, 11, 3214-3229.	9.4	24
9	Identifying and targeting the Achilles heel of a recalcitrant cancer. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	5
10	Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. <i>Cancer Cell</i> , 2021, 39, 1479-1496.e18.	16.8	155
11	Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. <i>Journal of Hematology and Oncology</i> , 2021, 14, 170.	17.0	26
12	MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer. <i>iScience</i> , 2021, 24, 103224.	4.1	13
13	SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1823-1835.	1.1	234
14	Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer. <i>Cell Reports</i> , 2020, 33, 108444.	6.4	118
15	CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future. <i>Frontiers in Oncology</i> , 2020, 10, 1387.	2.8	247
16	Should WEE(1) CHK(1) in on the FAM(122A)ily?. <i>Molecular Cell</i> , 2020, 80, 377-378.	9.7	1
17	Lineage plasticity in cancer: a shared pathway of therapeutic resistance. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 360-371.	27.6	263
18	STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. <i>Journal of Thoracic Oncology</i> , 2020, 15, 777-791.	1.1	94

#	ARTICLE	IF	CITATIONS
19	The MEK5-ERK5 Kinase Axis Controls Lipid Metabolism in Small-Cell Lung Cancer. <i>Cancer Research</i> , 2020, 80, 1293-1303.	0.9	49
20	Targeted Therapies and Biomarkers in Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 741.	2.8	65
21	MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. <i>Nature Communications</i> , 2019, 10, 3485.	12.8	54
22	Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2152-2163.	1.1	80
23	Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2019, 9, 646-661.	9.4	555
24	Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 346-357.	7.0	14
25	Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. <i>Translational Lung Cancer Research</i> , 2018, 7, 50-68.	2.8	96
26	CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. <i>Cancer Research</i> , 2017, 77, 3870-3884.	0.9	163
27	Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6239-6253.	7.0	93
28	Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 28575-28587.	1.8	157
29	Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. <i>Oncotarget</i> , 2017, 8, 73419-73432.	1.8	74
30	Focal adhesion kinase induces matrix metalloproteinase-2 by involving $\beta$ 1-mediated signaling in breast cancer cell, MCF-7. <i>Acta Medica International</i> , 2015, 2, 29.	0.2	0
31	Genome Wide Expression Profiling during Spinal Cord Regeneration Identifies Comprehensive Cellular Responses in Zebrafish. <i>PLoS ONE</i> , 2014, 9, e84212.	2.5	76
32	Laminin induces matrix metalloproteinase-9 expression and activation in human cervical cancer cell line (SiHa). <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 347-357.	2.5	23
33	Culture of human breast cancer cell line (MDA-MB-231) on fibronectin-coated surface induces pro-matrix metalloproteinase-9 expression and activity. <i>Tumor Biology</i> , 2011, 32, 129-138.	1.8	42
34	Epigallocatechin-3-gallate (EGCG) downregulates gelatinase-B (MMP-9) by involvement of FAK/ERK/NF $\kappa$ B and AP-1 in the human breast cancer cell line MDA-MB-231. <i>Anti-Cancer Drugs</i> , 2010, 21, 632-644.	1.4	94
35	Fibronectin-integrin mediated signaling in human cervical cancer cells (SiHa). <i>Molecular and Cellular Biochemistry</i> , 2010, 336, 65-74.	3.1	35
36	All-trans retinoic acid (ATRA) downregulated MMP-9 by modulating its regulatory molecules. <i>Cell Adhesion and Migration</i> , 2010, 4, 409-418.	2.7	33

#	ARTICLE	IF	CITATIONS
37	Fibronectin induces matrix metalloproteinase-9 (MMP-9) in human laryngeal carcinoma cells by involving multiple signaling pathways. <i>Biochimie</i> , 2010, 92, 1422-1434.	2.6	51
38	Culture of K562 human myeloid leukemia cells in presence of fibronectin expresses and secretes MMP-9 in serum-free culture medium. <i>International Journal of Clinical and Experimental Pathology</i> , 2010, 3, 288-302.	0.5	5
39	Multifunctional effect of epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7. <i>Life Sciences</i> , 2009, 84, 194-204.	4.3	90